Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ARGX-110 + Azacitidine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ARGX-110||JNJ-74494550|Cusatuzumab||ARGX-110 is a monoclonal antibody that targets CD70, resulting in inhibition of CD70-CD27-mediated signaling and enhanced immune response against CD70-expressing tumor cells (PMID: 28765328, PMID: 24492296).|
|Azacitidine||Vidaza||azacytidine|CC-486|5-azacytidine|5-AC|U-18496||DNMT inhibitor (Pan) 5||Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04264806||Phase II||ARGX-110 + Azacitidine Azacitidine||A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)||Not yet recruiting|
|NCT04023526||Phase II||ARGX-110 + Azacitidine||A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy||Recruiting|
|NCT04150887||Phase I||ARGX-110 + Azacitidine + Venetoclax ARGX-110 + Venetoclax ARGX-110 + Azacitidine||Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia||Recruiting|